Vestal Point Capital LP Has $7.68 Million Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Vestal Point Capital LP grew its holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 1.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 850,000 shares of the company’s stock after purchasing an additional 10,000 shares during the period. Vestal Point Capital LP’s holdings in Lexeo Therapeutics were worth $7,684,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. BNP Paribas Financial Markets increased its stake in Lexeo Therapeutics by 184.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares during the period. Values First Advisors Inc. acquired a new position in shares of Lexeo Therapeutics in the third quarter worth $67,000. American International Group Inc. purchased a new stake in shares of Lexeo Therapeutics during the first quarter worth $79,000. MetLife Investment Management LLC boosted its position in Lexeo Therapeutics by 121.5% during the third quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock valued at $129,000 after purchasing an additional 7,803 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in Lexeo Therapeutics by 37.3% in the second quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock valued at $214,000 after purchasing an additional 3,627 shares in the last quarter. 60.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Richard Nolan Townsend sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $8.10, for a total transaction of $40,500.00. Following the completion of the transaction, the chief executive officer now directly owns 120,695 shares in the company, valued at $977,629.50. The trade was a 3.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 12,500 shares of company stock valued at $113,300. 4.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on LXEO shares. HC Wainwright boosted their price target on Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. Leerink Partners decreased their target price on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Wednesday, November 13th. Chardan Capital raised their price target on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday, August 13th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $23.80.

Lexeo Therapeutics Price Performance

Shares of Lexeo Therapeutics stock opened at $7.83 on Friday. Lexeo Therapeutics, Inc. has a 1-year low of $5.77 and a 1-year high of $22.33. The firm has a fifty day simple moving average of $8.43 and a 200-day simple moving average of $11.83. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.